Journey Medical (DERM) Aktienübersicht
Journey Medical Corporation, ein pharmazeutisches Unternehmen im kommerziellen Stadium, das sich auf die Entwicklung und Vermarktung von pharmazeutischen Produkten für die Behandlung von Hautkrankheiten in den Vereinigten Staaten konzentriert. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 6/6 |
| Künftiges Wachstum | 5/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
Bei unseren Risikoprüfungen wurden keine Risiken für DERM festgestellt.
DERM Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Journey Medical Corporation Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$6.99 |
| 52-Wochen-Hoch | US$9.56 |
| 52-Wochen-Tief | US$4.31 |
| Beta | 1.1 |
| 1 Monat Veränderung | -9.81% |
| 3 Monate Veränderung | 4.33% |
| 1 Jahr Veränderung | -4.25% |
| 3 Jahre Veränderung | 148.75% |
| 5 Jahre Veränderung | n/a |
| Veränderung seit IPO | -26.42% |
Aktuelle Nachrichten und Updates
DERM: Positive Operating Profit Will Support Ongoing Prescription And Pricing Momentum
Analysts have lifted the fair value estimate for Journey Medical from $11.00 to $13.00. They point to higher profit margin assumptions, a slightly higher discount rate, and recent research that highlights stronger prescription trends, better net revenue per script, and the company's first reported positive GAAP operating profit as key supports for the higher target.
DERM: Expanded Access And Parent Cash Backing Will Support Future Value
Analysts have raised their price target on Journey Medical by $1, citing updated valuations that reflect the implied value of its shares within Fortress Biotech. Supporting research keeps key assumptions unchanged, including fair value, discount rate, revenue growth, profit margin, and future P/E.Recent updates
DERM: Positive Operating Profit Will Support Ongoing Prescription And Pricing Momentum
Analysts have lifted the fair value estimate for Journey Medical from $11.00 to $13.00. They point to higher profit margin assumptions, a slightly higher discount rate, and recent research that highlights stronger prescription trends, better net revenue per script, and the company's first reported positive GAAP operating profit as key supports for the higher target.DERM: Expanded Access And Parent Cash Backing Will Support Future Value
Analysts have raised their price target on Journey Medical by $1, citing updated valuations that reflect the implied value of its shares within Fortress Biotech. Supporting research keeps key assumptions unchanged, including fair value, discount rate, revenue growth, profit margin, and future P/E.DERM: Expanded Access Progress Will Support Future Parent Group Value
Narrative Update on Journey Medical The analyst price target for Journey Medical has been adjusted from $13.25 to $13.50, as analysts factor in updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples influenced in part by recent Street research attention on both Journey Medical and its parent Fortress Biotech. Analyst Commentary Recent Street research around Journey Medical and Fortress Biotech has given investors more context on how analysts are thinking about value, execution, and growth for Journey Medical within the broader group structure.DERM: Expanded Access And Execution Progress Will Support Future Upside
Narrative Update: Journey Medical Analyst Price Target Shift Analysts have lifted their price target on Journey Medical by $1 to $13.25, citing updated research that supports a higher valuation for the shares. Analyst Commentary Analysts highlighting the move to a US$13.25 price target are framing it as a recalibration based on refreshed research rather than a wholesale shift in the story.DERM: At The Market Liquidity And Margin Progress Will Support Future Upside
Analysts have raised their price target on Journey Medical by $1 to $13.25, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E to support the new view. Analyst Commentary Bullish Takeaways Bullish analysts view the higher US$13.25 price target as better aligned with their updated fair value work, suggesting the prior target did not fully reflect their assumptions on earnings power and risk.Slow Reimbursement And Competitive Pressures Will Challenge Dermatology Prescriptions Yet Support Gradual Improvement
Catalysts About Journey Medical Journey Medical focuses on commercializing prescription dermatology treatments, with Emrosi as its flagship oral therapy for inflammatory rosacea lesions. What are the underlying business or industry changes driving this perspective?DERM: At The Market Offering And Margin Progress Will Drive Future Upside
Analysts have adjusted their price target for Journey Medical to $13.25 from $13.50, citing updated views on revenue growth, profit margins, and the stock's future P/E multiple as reflected in recent Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as reflecting confidence that recent revenue trends and cost controls can support the revised P/E assumption used in their models.
Rosacea Market Tailwinds And Payer Access Will Drive Durable Long Term Dermatology Upside
Catalysts About Journey Medical Journey Medical focuses on commercializing prescription dermatology products, including Emrosi for rosacea, in the U.S. market. What are the underlying business or industry changes driving this perspective?DERM: At The Market Equity Offering Will Support Future Upside Potential
Analysts have maintained their price target for Journey Medical at $13.50, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E expectations. What's in the News Journey Medical filed a follow-on equity offering for its common stock, signaling plans to raise additional capital through the equity market (Key Developments).DERM: Phase 1 Rosacea Microbiome Safety Will Support Future Upside Potential
Analysts have maintained their price target for Journey Medical at $13.50, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin and future P/E for the company. What's in the News Journey Medical filed a follow on equity offering for its common stock as an at the market offering, giving the company the option to issue new shares into the market over time (Key Developments).DERM: Phase 1 Rosacea Microbiome Safety Will Drive Future Upside
Analysts have maintained their price target on Journey Medical at US$13.50, with only slight model adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions supporting this stable view. What's in the News Journey Medical filed a follow-on equity offering for its common stock as an at-the-market offering, indicating potential future issuance of additional shares (Key Developments).DERM: Phase 1 Rosacea Microbiome Safety Will Support Future Upside
Analysts have reaffirmed their price target on Journey Medical at US$13.50, citing unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E as the basis for keeping their view steady. What's in the News Journey Medical filed a follow-on equity offering for its common stock, structured as an at-the-market offering.Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...DERM: Phase 3 Rosacea Efficacy And Microbiome Safety Will Drive Upside
Analysts have maintained their price target for Journey Medical at US$13.50. This steady view reflects unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E.DERM: Phase 3 Rosacea Data And Microbiome Safety Will Support Further Upside
Analysts have modestly reiterated their outlook on Journey Medical, maintaining a price target of $13.50 per share as slight tweaks to the discount rate, revenue growth assumptions, profit margin, and future P E estimates leave their valuation framework effectively unchanged. What's in the News Phase 1 trial results for DFD-29, marketed as Emrosi, showed no detectable impact on skin, gastrointestinal, or vaginal microflora over 16 weeks and confirmed the therapy was well tolerated in healthy adults, supporting its use in moderate to severe rosacea (Key Developments).DERM: Phase 3 Rosacea Efficacy And Safety Will Likely Support Further Upside
Analysts have modestly reiterated their confidence in Journey Medical, maintaining their price target at 13.50 dollars. Unchanged near term revenue growth, profitability expectations, and valuation multiples continue to support the current fair value outlook.DERM: Recent Trial Success Will Likely Drive Shares Toward Upside Potential
Analysts have revised their price target for Journey Medical, maintaining it at $13.50 per share. Updates to projected profit margin and future valuation metrics prompted a reassessment of the company's growth outlook.DERM: Improved Margins and Clinical Results Are Expected to Drive Shares Higher
Analysts have raised their price target for Journey Medical from $11.80 to $13.50. They cite improved profit margin expectations despite slightly adjusted forecasts for revenue growth and discount rates.US$11.50 - That's What Analysts Think Journey Medical Corporation (NASDAQ:DERM) Is Worth After These Results
NasdaqCM:DERM 1 Year Share Price vs Fair Value Explore Journey Medical's Fair Values from the Community and select...Emrosi Launch Will Expand Rosacea Treatment Options
Journey Medical’s sharply improved net profit margin and lower future P/E ratio signal enhanced profitability and valuation appeal, driving the consensus analyst price target up from $10.50 to $11.50. What's in the News Pharmacy benefit coverage for Emrosi™ increased to 65% of US commercial lives, up from 29% in May.Is Journey Medical (NASDAQ:DERM) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Is Journey Medical (NASDAQ:DERM) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Emrosi Launch Will Expand Rosacea Treatment Options
Emrosi's launch and favorable Phase III results are expected to boost revenue growth and enhance net margins through existing operations.A Piece Of The Puzzle Missing From Journey Medical Corporation's (NASDAQ:DERM) 26% Share Price Climb
Journey Medical Corporation ( NASDAQ:DERM ) shares have continued their recent momentum with a 26% gain in the last...Journey Medical (NASDAQ:DERM) Has Debt But No Earnings; Should You Worry?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Market Cool On Journey Medical Corporation's (NASDAQ:DERM) Revenues Pushing Shares 26% Lower
Unfortunately for some shareholders, the Journey Medical Corporation ( NASDAQ:DERM ) share price has dived 26% in the...Journey Medical Corporation (NASDAQ:DERM) Shares Fly 31% But Investors Aren't Buying For Growth
Journey Medical Corporation ( NASDAQ:DERM ) shares have had a really impressive month, gaining 31% after a shaky period...Here's Why Journey Medical (NASDAQ:DERM) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Journey Medical Corporation (NASDAQ:DERM) Not Doing Enough For Some Investors As Its Shares Slump 31%
To the annoyance of some shareholders, Journey Medical Corporation ( NASDAQ:DERM ) shares are down a considerable 31...Aktionärsrenditen
| DERM | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | -5.3% | 1.4% | 1.8% |
| 1Y | -4.2% | 49.6% | 13.3% |
Rendite im Vergleich zur Industrie: DERM unter dem Niveau der Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 49.6% erzielte.
Rendite vs. Markt: DERM hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 13.3 erzielte.
Preisvolatilität
| DERM volatility | |
|---|---|
| DERM Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 8.3% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stabiler Aktienkurs: DERM hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: DERMDie wöchentliche Volatilität (8%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2014 | 58 | Claude Maraoui | journeymedicalcorp.com |
Journey Medical Corporation, ein pharmazeutisches Unternehmen im kommerziellen Stadium, das sich auf die Entwicklung und Vermarktung von pharmazeutischen Produkten für die Behandlung von Hautkrankheiten in den Vereinigten Staaten konzentriert. Zu den vermarkteten Produkten des Unternehmens gehören Qbrexza, ein medizinisches Tuch zur Behandlung der primären axillären Hyperhidrose, Accutane, ein orales Isotretinoin-Medikament zur Behandlung von schwerer rezidivierender nodulärer Akne, und Amzeeq, eine topische Formulierung von Minocyclin zur Behandlung von entzündlichen Läsionen bei nicht-nodulärer mäßiger bis schwerer Akne vulgaris. Darüber hinaus bietet das Unternehmen Zilxi, eine topische Minocyclin-Behandlung für entzündliche Läsionen bei Rosazea, Emrosi zur Behandlung entzündlicher Läsionen bei Rosazea, Exelderm Creme und Lösung zur Behandlung von Pilzinfektionen der Haut; und Targadox, ein orales Doxycyclin-Präparat zur Zusatztherapie bei schwerer Akne, sowie Luxamend, eine Emulsion auf Wasserbasis, die ein feuchtes Heilungsmilieu für oberflächliche Wunden, kleinere Schnitt- oder Schürfwunden, Hautgeschwüre, Spenderstellen, Verbrennungen ersten und zweiten Grades, einschließlich Sonnenbrand, und Strahlendermatitis bietet.
Journey Medical Corporation's Grundlagenzusammenfassung
| DERM grundlegende Statistiken | |
|---|---|
| Marktanteil | US$206.32m |
| Gewinn(TTM) | -US$6.10m |
| Umsatz(TTM) | US$68.18m |
Ist DERM zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| DERM Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$68.18m |
| Kosten der Einnahmen | US$23.56m |
| Bruttogewinn | US$44.63m |
| Sonstige Ausgaben | US$50.73m |
| Gewinn | -US$6.10m |
Zuletzt gemeldete Gewinne
Jun 30, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.22 |
| Bruttomarge | 65.45% |
| Nettogewinnspanne | -8.95% |
| Schulden/Eigenkapital-Verhältnis | 79.3% |
Wie hat sich DERM auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/09/21 20:34 |
| Aktienkurs zum Tagesende | 2026/09/21 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Journey Medical Corporation wird von 5 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Scott Henry | Alliance Global Partners |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Kalpit Patel | B. Riley Securities, Inc. |